Palvella Therapeutics, Inc. - Common Stock (NQ: PVLA )

20.74 -0.25 (-1.19%)

Streaming Delayed Price Updated: 2:41 PM EST, Feb 19, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	18,277
Open	20.80
Bid (Size)	20.30 (1)
Ask (Size)	20.60 (1)
Prev. Close	20.99
Today's Range	20.74 - 21.70
52wk Range	11.17 - 21.02
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

February 10, 2025

From Palvella Therapeutics Inc.

Via GlobeNewswire

This Intuitive Machines Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday

February 05, 2025

Via Benzinga

Performance

YTD	+72.83%	+72.83%
1 Month	+57.12%	+57.12%
3 Month	+61.65%	+61.65%
6 Month	+61.65%	+61.65%
1 Year	+61.65%	+61.65%

More News

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies

January 10, 2025

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations

January 08, 2025

From Palvella Therapeutics Inc.

Via GlobeNewswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.